Hoping to beat the ASX 200? I'd consider buying these 3 ASX shares

Analysts think these shares can outperform the market.

| More on:
Man in an office celebrates at he crosses a finish line before his colleagues.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Historically, the ASX 200 index has generated a return of approximately 10% per annum.

This means that if you want to achieve market-beating returns, you're going to need to achieve a return beyond that.

This is easier said than done. A lot of fund managers struggle to beat the market. It is for this reason that Warren Buffett has often suggested that investors should just buy an index fund and settle for that.

But it isn't impossible. In fact, Buffett has a long track record of delivering market-beating returns for Berkshire Hathaway (NYSE: BRK.B).

So, if I were going to attempt to beat the ASX 200 index, I would follow the Oracle of Omaha's investment strategy.

That strategy is quite simply building a diverse portfolio filled with the highest quality companies you can find with sustainable competitive advantages and fair valuations. This has delivered great results for Buffett and Berkshire Hathaway, and I believe it could do the same for others.

But which ASX shares tick the boxes? Three that have been tipped as buys for investors to consider are listed below:

CSL Ltd (ASX: CSL)

This biotechnology company's shares have been dragged lower over the last 12 months due partly to a slower-than-expected margin recovery and a disappointing clinical trial result.

Analysts at Morgans think investors should be taking advantage of this. The broker has the ASX share on its best ideas list with an add rating and a $315.40 price target.

This suggests that a potential return of almost 15% is possible over the next 12 months.

ResMed Inc (ASX: RMD)

Another high-quality ASX share that remains down meaningfully on a 12-month basis is sleep treatment company ResMed. This has been driven by concerns that weight loss wonder drugs will negatively impact its growth.

Morgans doesn't believe this will be the case. Its analysts "see these products having little impact on the large, underserved sleep disorder breathing market, and do not view them as category killers."

The broker has an add rating and a $32.82 price target on its shares, which implies a potential upside of 14% for investors.

Xero Ltd (ASX: XRO)

Finally, UBS thinks that the recent weakness has created an opportunity for investors to buy this ASX share.

The broker believes that the cloud accounting platform provider can grow its key average revenue per user metric by a compound annual growth rate of 6.5% for the next five years. Though, it concedes that even this may be conservative based on potential price rises and plan upgrades.

UBS has a buy rating and a $141.90 price target on Xero's shares. This suggests a potential upside of 20% for investors from current levels.

Motley Fool contributor James Mickleboro has positions in CSL, ResMed, and Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Berkshire Hathaway, CSL, ResMed, and Xero. The Motley Fool Australia has positions in and has recommended ResMed and Xero. The Motley Fool Australia has recommended Berkshire Hathaway and CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

happy investor, share price rise, increase, up
Growth Shares

3 fantastic ASX 200 growth shares to buy in 2025

Analysts have good things to say about these buy-rated shares.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
Growth Shares

The ASX 200 stock with 'a $200 billion gross profit opportunity'

Experts believe this stock has excellent potential.

Read more »

A young girl and boy drinking milk in a garden setting
Growth Shares

2 ASX growth shares set to skyrocket in the next 12 months

These stocks have a lot of potential according to experts.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

2 no-brainer ASX 200 shares to consider buying with just $1,000

Analysts rate these top stocks very highly. Let's find out why.

Read more »

A happy laughing surfer couple surfing together.
Growth Shares

If I were in my 20s, I'd buy these ASX shares for growth

I think these investments could be great picks for younger Aussies.

Read more »

Hand holding Australian dollar (AUD) bills, symbolising ex dividend day. Passive income.
Growth Shares

Invest $5,000 into these ASX 200 shares in 2025

Analysts think these shares could be top options for an investment in 2025.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Growth Shares

3 explosive ASX growth shares to buy now

Analysts have good things to say about these growth shares.

Read more »

Happy man holding Australian dollar notes, representing dividends.
Growth Shares

Invest $5,000 into these ASX 200 growth shares in December

Analysts at Bell Potter and Goldman Sachs are bullish on these names.

Read more »